SCHEMBL3835546

SCHEMBL3835546

CC(C)(C)OC(=O)Nc1ccccc1NC(=O)c1ccc(CN(CCCN2CCCC2)C(=O)Nc2ccc3c(c2)OCCO3)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIR O00625 2/20 0.44
ALDH1A1 P00352 5/20 0.43
LMNA P02545 3/20 0.43
RAB9A P51151 2/20 0.43
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43
KDM4E B2RXH2 4/20 0.42
HPGD P15428 3/20 0.42
HSD17B10 Q99714 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GLA P06280 1/20 0.42
MCHR1 Q99705 3/20 0.42
BRAF P15056 1/20 0.42
GSK3B P49841 1/20 0.42
HSF1 Q00613 1/20 0.42
TSHR P16473 3/20 0.42
KDM1A O60341 1/20 0.42
ACHE P22303 1/20 0.41
BACE1 P56817 1/20 0.41
EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2475671 0.95 TSHR (0.43) PIRALDH1A1LMNARAB9ATP53
SCHEMBL3835829 0.95 ALDH1A1 (0.50) ALDH1A1LMNARAB9ATP53POLB
SCHEMBL3834058 0.93 KDM1A (0.41) PIRALDH1A1LMNARAB9ATP53
SCHEMBL3835037 0.93 KDM4E (0.45) PIRALDH1A1LMNARAB9ATP53
SCHEMBL3836123 0.92 LMNA (0.51) ALDH1A1LMNARAB9ATP53POLB
SCHEMBL3830687 0.91 ALDH1A1 (0.51) ALDH1A1LMNARAB9ATP53POLB
SCHEMBL3835723 0.91 RAB9A (0.44) ALDH1A1LMNARAB9ATP53POLB
SCHEMBL3831096 0.90 EPHX2 (0.43) ALDH1A1LMNARAB9ATP53POLB
SCHEMBL3834327 0.89 HDAC1 (0.48) ALDH1A1LMNARAB9ATP53POLB
SCHEMBL3232031 0.88 USP2 (0.41) PIRALDH1A1LMNARAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 PIR 4257/4885ALDH1A1 1040/4885LMNA 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.